CervoMed presents Phase 2a biomarker data at AAIC; neflamapimod reduces plasma GFAP in early DLB

CervoMed Inc.

Poster at AAIC 2024: baseline plasma GFAP highly correlated with CDR-SB dementia severity in DLB patients.
In early-stage DLB (no AD co-pathology), neflamapimod reduced plasma GFAP by mean 10.6 pg/mL vs placebo increase of 14.1 pg/mL (p=0.04).
Reduction in GFAP correlated with improvement in CDR-SB in neflamapimod-treated early DLB patients (r=0.54, p=0.04).
Fully enrolled RewinD-LB Phase 2b trial to report topline primary efficacy results in December 2024.
Management to participate in fireside chat at Canaccord Genuity 44th Annual Growth Conference on August 13, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.